# PharmaCyte Biotech, Inc.: overview PMCB · Nasdaq · CIK 1157075 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Apr 30 Pages: [Overview](/companies/pmcb.md) · [Financials](/companies/pmcb/financials.md) · [Filings](/companies/pmcb/filings.md) · [Insiders](/companies/pmcb/insiders.md) Latest reported revenue: [$0](/filings/0001683168-26-007106.md) for Q1 FY2027, three months to 2026-07-31, from the 10-Q filed Sep 14, 2026 (XBRL us-gaap:Revenues, accession 0001683168-26-007106). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | [0.0](/filings/0001683168-25-009259.md) | [0.0](/filings/0001683168-26-001917.md) | [0.0 d](/filings/0001683168-26-005836.md) | [0.0](/filings/0001683168-26-007106.md) | [0.0](/filings/0001683168-25-009259.md) | [0.0](/filings/0001683168-26-001917.md) | [0.0 d](/filings/0001683168-26-005836.md) | [0.0](/filings/0001683168-26-007106.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.39)](/filings/0001683168-25-009259.md) | [(0.44)](/filings/0001683168-26-001917.md) | not reported | [(1.23)](/filings/0001683168-26-007106.md) | [(1.24)](/filings/0001683168-25-009259.md) | [(0.17)](/filings/0001683168-26-001917.md) | not reported | [(0.54)](/filings/0001683168-26-007106.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-04-30) | FY2023 (2023-04-30) | FY2024 (2024-04-30) | FY2025 (2025-04-30) | FY2026 (2026-04-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | [0.0](/filings/0001683168-23-005175.md) | [0.0](/filings/0001683168-24-005575.md) | [0.0](/filings/0001683168-25-005821.md) | [0.0](/filings/0001683168-26-005836.md) | [0.0](/filings/0001683168-26-005836.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.27)](/filings/0001683168-23-005175.md) | [(0.22)](/filings/0001683168-24-005575.md) | [(1.80)](/filings/0001683168-25-005821.md) | [3.19](/filings/0001683168-26-005836.md) | [(2.77)](/filings/0001683168-26-005836.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pmcb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $218.2k | 283,381 | | Reduced −76,166 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $95.7k | 124,247 | | Reduced −71,413 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $66.3k | 86,100 | Call | Reduced −74,100 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $43.7k | 56,778 | | Added +5,311 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $34.5k | 44,853 | | New +44,853 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $29.3k | 37,987 | | Reduced −18,513 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $26.3k | 34,180 | | Reduced −18,182 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $25.1k | 32,624 | | Reduced −2,977 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $23.1k | 30,064 | | Added +18,534 | | [Schonfeld Strategic Advisors LLC](/funds/1665241.md) | 2026-06-30 | $20.7k | 26,926 | | Reduced −83 | ## Recent filings [All 410 filings](/companies/pmcb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 21:00 ET | [8-K](/filings/0001683168-26-007934.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001683168-26-007934 | | 2026-09-14 | 20:05 ET | [10-Q](/filings/0001683168-26-007106.md) | Quarterly report, period 2026-07-31 | 0001683168-26-007106 | | 2026-07-29 | 20:58 ET | [10-K](/filings/0001683168-26-005836.md) | Annual report, period 2026-04-30 | 0001683168-26-005836 | | 2026-04-02 | 20:19 ET | [8-K](/filings/0001683168-26-002613.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001683168-26-002613 | | 2026-03-17 | 19:49 ET | [10-Q](/filings/0001683168-26-001917.md) | Quarterly report, period 2026-01-31 | 0001683168-26-001917 | | 2026-03-09 | 10:02 ET | [DEF 14A](/filings/0001683168-26-001593.md) | Proxy statement, period 2026-03-30 | 0001683168-26-001593 | | 2025-12-18 | 22:04 ET | [10-Q](/filings/0001683168-25-009259.md) | Quarterly report, period 2025-10-31 | 0001683168-25-009259 | | 2025-12-05 | 22:00 ET | [8-K](/filings/0001683168-25-008947.md) | 3.01 Delisting notice | 0001683168-25-008947 | | 2025-11-18 | 21:29 ET | [SCHEDULE 13D/A](/filings/0001683168-25-008515.md) | Ownership report, active investor, amended | 0001683168-25-008515 | | 2025-11-18 | 21:05 ET | [8-K/A](/filings/0001683168-25-008512.md) | 9.01 Financial statements and exhibits | 0001683168-25-008512 | ## Latest annual report [Form 10-K for the fiscal year ended Apr 30, 2026](/filings/0001683168-26-005836.md), filed Jul 29, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1157075 - Tickers: PMCB - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.